Cargando…

Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer

The impact of ctDNA changes after chemotherapy on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) remains unclear. The present study evaluated the clinical implications of the early change in ctDNA levels as a predictor of objective response and clinical outcome in mCRC pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osumi, Hiroki, Shinozaki, Eiji, Yamaguchi, Kensei, Zembutsu, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874682/ https://www.ncbi.nlm.nih.gov/pubmed/31758080 http://dx.doi.org/10.1038/s41598-019-53711-3

Ejemplares similares

Clinical utility of circulating tumor DNA for colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2019)

Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer
por: Osumi, Hiroki, et al.
Publicado: (2020)

Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2021)

Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation
por: Udagawa, Shohei, et al.
Publicado: (2023)

Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy
por: Osumi, Hiroki, et al.
Publicado: (2020)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017)

Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting
por: Nakayama, Izuma, et al.
Publicado: (2020)

Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2017)

Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
por: Fukuda, Koshiro, et al.
Publicado: (2023)

Immunotherapy in Colorectal Cancer: Current and Future Strategies
por: Ooki, Akira, et al.
Publicado: (2021)

Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
por: Osumi, Hiroki, et al.
Publicado: (2015)

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer
por: Nakayama, Izuma, et al.
Publicado: (2018)

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2020)

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
por: Osumi, Hiroki, et al.
Publicado: (2015)

Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases
por: Ichida, Hirofumi, et al.
Publicado: (2019)

Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol
por: Osumi, Hiroki, et al.
Publicado: (2022)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
por: Yao, Jiannan, et al.
Publicado: (2018)

Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting
por: Hatori, Masahiro, et al.
Publicado: (2021)

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2019)

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Fukuda, Naoki, et al.
Publicado: (2018)

Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis
por: Uesato, Yasunori, et al.
Publicado: (2020)

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2023)

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2016)

Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018
por: Nakayama, Izuma, et al.
Publicado: (2022)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer
por: Thomsen, Caroline B., et al.
Publicado: (2020)

Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
por: Ooki, Akira, et al.
Publicado: (2023)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake
por: Osumi, Hiroki, et al.
Publicado: (2018)

NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
por: Raunkilde, Louise, et al.
Publicado: (2022)

Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer
por: Takayama, Yuji, et al.
Publicado: (2018)

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
por: Ooki, Akira, et al.
Publicado: (2023)

Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial
por: Ooki, Akira, et al.
Publicado: (2022)

Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer
por: Jia, Ning, et al.
Publicado: (2021)

Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma
por: Eskander, Nancy Samir, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2h8lqn3pj1cpi1p6l1k6e133hh